Figure 1.

Morphology, Proliferation, and Differentiation of DLL4 and PDGF-BB-Treated SCs

(A) Phase contrast images of untreated and DLL4 and PDGF-BB-treated SCs isolated from CD1 mice.

(B) Graph quantifies circularity ratio, where 1 = circle and 0 = line (n = 3).

(C) Proliferation curves of untreated and treated SCs over time (n = 3). Box highlights treatment switch.

(D–F) Immunofluorescence analysis of SCs isolated from TN-AP^cre:TdTomato mice expanded for 2 weeks prior to treatment, or maintained in untreated conditions. Cells pulsed for 2 h with EdU and co-immunostained with Ki67 (arrowheads: nuclear signal) (N = 3) (D). Quantified in (E and F).

(G) Immunofluorescence images of untreated and treated SCs differentiated into myotubes in low mitogen medium for 4 days and immunostained for myosin heavy chain (MyHC) and Hoechst (N = 3 mice and 4 experiments).

(H) Untreated and treated SCs differentiated in low mitogen medium supplemented with 660 ng/mL of the γ-secretase inhibitor L-685,458 to inhibit Notch signaling (N = 3).

Data: means ± SEM. Statistical significance based on paired (E and F) or unpaired (G and H) Student's t test; ^∗p < 0.05; n.s., not significant. Scale bars, 25 μm (D) and 100 μm (A, G, and H).